1 / 50

Chemotherapy Induced Cardiotoxicity

Chemotherapy Induced Cardiotoxicity. Prof. Drs. Hanan Amin . Chemotherapy :- radiotherapy or combined use of both have the potential to cause cardiotoxicity . . Chemotherapy Induced Cardiotoxicity. • The number of long-term survivors of cancer is increasing

caprice
Download Presentation

Chemotherapy Induced Cardiotoxicity

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Chemotherapy InducedCardiotoxicity Prof. Drs. Hanan Amin

  2. Chemotherapy :- radiotherapy or combined use of both have the potential to cause cardiotoxicity.

  3. Chemotherapy InducedCardiotoxicity • The number of long-term survivors of cancer is increasing • By 2010 1 of every 450 child may be a survivor of malignant disease • Many will have been exposed to anthracyclines – Effective in treating broad spectrum of malignancies

  4. Definition : • Cardiotoxicity is defined as one or more of the following : • Cardiomyopathy in terms of reduction of left ventricular ejection fraction (LVEF) either global or more severe in the septum. • Symptoms associated with heart failure Hf e.g. pulmonary roles, peripheral oedema, hepatomegally,….. • Signs associated with Hf such as S3 , gallop, tachycardia or both. • Reduction in LVEF from baseline that is the range of less than or equal to 5% to less than 55% with accompanying signs or symptoms of Hf, or a reduction in LVEF in the range of equal to or greater than 10% to less than 55% without accompanying signs or symptoms.

  5. Chemotheraphy causing cardiotoxicity 1-Anthracyclines:- -Doxorubicin -Daunorubicin - Idarubicin 2-Alkylators:- -Cyclophosphamide -Cisplatin 3-Antimetabolite:- -5 –flouracil 4-Antimicrotubule:- -Vinca Alkaloid 5-Cytokaines:- -Interlukin -Interferon 6-Atra

  6. Radiation causing cardiotoxicity Cardiac doses of radiation up to 25 Gy. Are generally safe. ,However, it may involve all cardiac structures :- 1-Acute true medical and or / surgery emergencies Eg. Tamponade,Ami,Arrest. 2-Cronic due to collagen deposition.

  7. Anthracycline Cardiotoxicity • Cytotoxic antibiotics • Daunorubicin, doxorubicin, epirubicin and idarubicin • Highly effective against hematologic and solid malignancies • First line defense in the management of many tumors

  8. Anthracycline Cardiotoxicity Incidence:- Anthrocycline induced cardiomyopathy is related to cumulative dose. It occurs in 11% of cancer patients after a cumulative dose of less than 400 mg/m2, 23% after 400-599 mg/m2, 47% after 500-799 mg/m2 and 100% after 800 mg/m2.

  9. Anthracycline Cardiotoxicity Leads to free radical formation – Molecules containing an odd number of electrons • H2O2, hydroxyl radicals, ect. – Are highly reactive and damaging to tissues • Peroxidation – Are countered by antioxidants and by intracellular enzymes

  10. Anthracycline Cardiotoxicity – Cardiac degradation of anthrcyclines leads to free radical formation (enzymatic) – Anthracyline-ferric iron complex are formed in the heart – Cardiac tissue has very limited capacity to deal with free radicals – Mitochondria are particularly susceptible to free radical damage

  11. Anthracycline Cardiotoxicity • Other anthracycline induced mechanisms of cell injury – Apoptosis – Elevated calcium accumulation in mitochondria – Modulation of cardiac gene expression

  12. Anthracycline Cardiotoxicity Adverse effects on the heart – Electrophysiological changes – Heart failure – Reduced exercise tolerance – Cardiomyopathy – Pericarditis – Myocarditis

  13. Anthracycline Cardiotoxicity Risk Factors – Dosing schedule • Single large dose > risk than smaller, frequent dosing • Bolus injection > risk than continuous infusion – Age of patient • > 65 YOA • < 4 YOA

  14. Anthracycline Cardiotoxicity Risk Factors – History of mediastinal irradiation • Amplifies preexisting CAD • Exacerbation of vascular injury • Pericardial effusion • Pericardial fibrosis (restrictive disease) • Myocardial fibrosis (valvular disease) – Preexisting heart disease and arterial hypertension

  15. Anthracycline Cardiotoxicity • Risk Factors – Simultaneous administration of other antineoplastic agents (cyclophosphomides, actinomycin D, bleomycin, cisplatin, methotraxate) – Poor nutrition – Diabetes – Gender

  16. Anthracycline Cardiotoxicity: Stages • Acute Toxicity:- • Occur anytime from initiation of theraphy up to 2 weeks after termination of ttt • – Rare • – Directly connected with the administration of a • single dose or after a course of the antibiotic

  17. Anthracycline Cardiotoxicity: Stages Acute Toxicity: – ECG changes • Often asymptomatic and rarely fatal • Synergistic action between drug and hypokalemia • Discontinue drug if occurs • Tends to be reversible • Result of an autonomic defect

  18. Anthracycline Cardiotoxicity: Stages Acute Toxicity: – Cardiac monitoring during dosing? • Not typically • History • Presence of CV risk factors • Previous dosage history

  19. Anthracycline Cardiotoxicity: Stages Subacute Toxicity – Occurs days to weeks post treatment – Rare and often asymptomatic – Toxic pericarditis and/or myocarditis – Appearance of CHF at this point is a harbinger of poor outcomes for the patient

  20. Anthracycline Cardiotoxicity: Stages • Chronic Cardiotoxicity Early onset – < 1 yr. post treatment – Dose dependent – Manifests itself as CHF secondary to cardiomyopathy – Exact incidence unclear • 1%-18% • May miss subtle declines in LV function

  21. Anthracycline Cardiotoxicity: Stages • Late onset-Cardiotoxicity – Takes years to decades to develop – Mortality estimated at 30-60%

  22. Anthracycline Cardiotoxicity: Stages • Late onset-Cardiotoxicity

  23. Anthracycline Cardiotoxicity: Stages • Late Cardiotoxicity – Characterized by • LV systolic failure (CHF) • Diastolic failure • Reduced cardiac contractility • Reduced cardiac compliance – Anatomic changes • Thinned ventricular walls, reduced heart weight • Cardiac fibrosis

  24. Anthracycline Cardiotoxicity: Stages Late Cardiotoxicity – Monitoring/detection • Needed but problematic – Long term follow ups absent – Very subtle – Diastolic failure • Stress Angiography • Left ventricular end-systolic wall stress

  25. Anthracycline Cardiotoxicity: HeartFailure

  26. DEFINITION OF HEART FAILURE (HF) – “A complex clinical syndrome that can result from any structural or functional cardiac disorder that impairs the ability of the ventricle to fill with or to eject blood” Braunwald – “The situation where the heart is incapable of maintaining a cardiac output adequate to accommodate metabolic needs and venous return” Katz

  27. Failed heart

  28. Anthracycline Cardiotoxicity: HeartFailure • Gross Changes – Increased ventricular volume – Increased then decreased ventricular wall thickness – These geometric changes increases wall tension and decreases pumping efficiency

  29. Anthracycline Cardiotoxicity: HeartFailure Microscope Changes – Mitochondrial defects – Diminished cardiac myocyte calcium handling properties – Decreased vascularization – Apoptosis – Fibrosis causing increased cardiac stiffness

  30. HEART FAILURE • Cardinal symptoms – Dizziness, fainting, fatigue or weakness – Weight gain (due to fluid buildup) – Exercise intolerance – Dyspnea – Possible fluid retention/edema • JVD • Ascities – Orthopnia

  31. stages ACC/AHA CLASSIFICATION – STAGE A • At high risk for developing HF, no structural damage to the heart – STAGE B • Structural damage, asymptomatic – STAGE C • Structural damage, symptomatic – STAGE D • End stage

  32. Criteria for cardiac function deterioration • ECG findings : • Prolonged QT interval. • complete heart block. • Ventricular ectopy. • ST elevation or depression. • T wave changes. • 2nd degree atrioventricular AV block.,

  33. Criteria for cardiac function deterioration • ECHO findings : • Fractional shortening (SF) • Left ventricular ejection fraction LVEF less than 55%. • Radioinuclide cardiac cineangiocardiography (RNA, MUGA when good ECHO can not be obtained.

  34. Criteria for cardiac function deterioration Monitoring cardiovascular toxicity – Monitor for arrhythmias, ischemic cardiac events, cardinal CHF symptoms and pericardial disease

  35. Treatment of congestive heart failure • Digoxin  improve vent. Contraclitiy. • Diuretics ↓NA, H2O retention • ACE inhibiting agents (captopril)  ↓ afterload. • Enalapril  ↑ contractility ↓ afterload. • Pts with cardio myopathy are at risk for vent. Arrhythmia. They should undergo a 24-hours ECG monitor on regular basis

  36. Prevention of cardiotoxicity – Prolonged infusion – 2nd generation anthracyclines • Synthethic • Idarubicin, epirubicin, zorubicin • CV events comparable at similar cytotoxic levels

  37. Prevention of cardiotoxicity – Use of oxygen free radical scavengers • Vitamin E, Q10-coenzyme, Vitamin C – Dexrazoxane • Chelates intracellular iron and reducing free radial levels • Reduces cardiac damage and allows higher anthracycline dosing

  38. Preventing cardiotoxicity – Probucol • Vitamin E derivative • Lipid lowering • Enhances antioxidants – Liposomal formulations • Pegylated liposomal doxorubicin (Caelyx) • Drug is delivered in a liposome • Better tumor delivery and longer half life in the blood

  39. Preventing cardiotoxicity Physical therapy implications – Patient education – PT awareness • History • CHF does not preclude therapeutic exercise

  40. Guidelines for long-term follow up: • Frequency of testing is determined by the cumulative anthracycline doses: • Total cumulative dose (TCD)< 300 mg/m2  perform an ECHO before every other course. • TCD > 300 mg/m2 with or without mediastinal radiation  perform ECHO or MUGA every course. • After comptetion of therapy all patients should perform an ECHO at 12 months after discontinuation of therapy. • Patients with normal studies at the end of 1yr post therapy may have an ECHO, ECG every 2-3 ys. • Patients with abnormal studies should perform more follow up.

  41. Cyclophosphomides • Associated with acute and subacute cardiac events • High dose regimens carry greater risk • Total dose per course best predictor of cardiotoxicity • Prior treatment with anthracycline or mediastinal irradiation increases risk • Long term affects are usually not seen in those who survive acute effects

  42. 5-Fluorouracil • Acute creates ischemic insult • Clinically ranges from angina pectoris to myocardial infarction • Rechallenge generally produces same effect • Withdraw 5-FU and initiate anti-ischemic therapy • Greater risk in patients with CAD

  43. Chemotherapy causing other CVeffects • Agents associated with hypotension • Etoposide (Vepesid) • Paclitaxel (Taxol) • Alemtuzumab (Campath) • Cetuximab (Erbitux) • Rituximab (Rituxan) • IL-2 • Denileukin (Ontak) • Interferon- • All-trans retinoic acid (Tretinoin) • Homoharringtonine

  44. Chemotherapy causing other CVeffects • Agents associated with hypertension • Bevacizumab (Avastin) • Cisplatinin (Platinol)

  45. Chemotherapy causing other CV effects • Agents associated with other toxic effects • Cardiac tamponade or endomyocardial fibrosis: busulfan (Myleran) • Hemorrhagic myocarditis: cyclophosphamide (Cytoxan) • Bradyarrhythmias: paclitaxel (Taxol), thalidomide (Thalomid) • Raynaud phenomenon: vinblastine (Velban) • Autonomic neuropathy: vincristine (Oncovin) • QT prolongation or torsades de pointes: arsenic trioxide (Trisenox) • Pulmonary fibrosis: bleomycin (Blenoxane)

More Related